Trial: 201806007

A phase I/II study to evaluate the tolerability and efficacy of BMS-813160 (CCR2/5 inhibitor) with nivolumab and gemcitabine and nab-paclitaxel in borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC)

Phase

I/II

Principal Investigator

Lim, Kian-Huat

Disease Site

Pancreas

Learn more about this study at: clinicaltrials.gov